Cozad Asset Management Inc. Lowers Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Cozad Asset Management Inc. cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.5% in the 3rd quarter, Holdings Channel reports. The fund owned 8,035 shares of the biopharmaceutical company’s stock after selling 655 shares during the quarter. Cozad Asset Management Inc.’s holdings in Gilead Sciences were worth $674,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. CarsonAllaria Wealth Management Ltd. boosted its holdings in shares of Gilead Sciences by 198.3% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 238 shares in the last quarter. nVerses Capital LLC bought a new stake in Gilead Sciences in the 3rd quarter worth approximately $25,000. Valued Wealth Advisors LLC boosted its stake in Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares in the last quarter. Cedar Wealth Management LLC grew its position in Gilead Sciences by 51.6% during the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 160 shares during the last quarter. Finally, Strategic Investment Solutions Inc. IL purchased a new position in shares of Gilead Sciences during the second quarter worth approximately $33,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD opened at $97.90 on Friday. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.32. The company has a 50-day simple moving average of $84.58 and a two-hundred day simple moving average of $74.67. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95. The firm has a market capitalization of $121.88 billion, a PE ratio of 119.39, a price-to-earnings-growth ratio of 3.13 and a beta of 0.17.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The firm’s revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.29 earnings per share. On average, analysts anticipate that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on GILD. Robert W. Baird increased their target price on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a report on Thursday. Wells Fargo & Company raised their price objective on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday. Leerink Partnrs raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. Piper Sandler increased their target price on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday. Finally, JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday. Eleven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $90.05.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the sale, the insider now owns 99,599 shares in the company, valued at approximately $9,113,308.50. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now owns 99,599 shares in the company, valued at approximately $9,113,308.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 62,437 shares of company stock valued at $5,374,825 in the last three months. 0.29% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.